CAR Small-Molecule Compound Products

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

In vitro CAR-T manufacturing, small molecule-mediated regulation of T cell differentiation can optimize the therapeutic effect of cellular immunotherapy. Studies have shown that many small molecules induce changes in protein and gene expression levels and affect cell proliferation and viability of T cell subsets. Creative Biolabs offers a wide range of small-molecule compounds that help enhance the therapeutic properties of CAR-T cells.

Fig.1 Different small-molecule compounds.¹

Our Small-Molecule Compound Products

Protein kinase inhibitors
Studies have shown that abnormal activation of protein kinases can negatively affect normal cell function, thereby inducing tumorigenesis. Protein kinase inhibitors include: Tyrosine kinase inhibitors (TKIs), Bruton's tyrosine kinase (BTK).
Signaling pathway-targeting inhibitors
In the process of targeting and killing tumors, CAR-T cells will cause different adverse reactions by affecting different signaling pathways. Targeting key mediators of signaling pathways or inhibiting these pathways with reagents may enhance CAR-T cell therapy. Such products include JAK inhibitors, PI3K inhibitors, and mTOR inhibitors.
Apoptosis regulators
CAR-T cells kill tumor cells by inducing cell apoptosis. Apoptosis inhibitors re-sensitize tumor cells to apoptosis in CAR-T cell therapy. Apoptosis inhibitors include Bcl-2 inhibitors.
Epigenetic modulators
Histone modification and DNA methylation are associated with epigenetic modification of the genome. This mechanism affects impaired signaling in the normal hematopoietic pathway. The main epigenetic modulators include HDAC inhibitors and demethylating drugs.
Immunomodulatory agents
Immunomodulatory drugs can affect the proliferation, differentiation, and function of T cells. The combination of CAR-T cell therapy and immunomodulatory drug improves prognosis in patients with multiple myeloma (MM). Immunomodulatory drugs include thalidomide and its derivatives pomalidomide and lenalidomide.
Cytokines
Cytokines enhance immune system function and transmit information to different cells. In the preparation of CAR-T cells, the addition of different cytokines can promote the growth of CAR-T cells. The current research on CAR-T cells and cytokine conjugations includes: IL-2, IL-7, IL-12, IL-15, IL-21, IL-33, etc.
Others
γ-secretase inhibitors (GSIs)
cyclooxygenase-2 inhibitors
proteasome inhibitors
selective nuclear export inhibitors,
Akt inhibitors, etc.

Creative Biolabs offers a full range of products and services for your CAR T-cell therapy. If you are interested in our products, or have any questions in the field of CAR, please feel free to contact us. Below are some CAR small-molecule compound products:

References

Gardner, T.J.; et al. Engineering CAR-T cells to activate small-molecule drugs in situ. Nat Chem Biol. (2022) 18, 216–225.
Cao, Xinping.; et al. "Small-molecule compounds boost CAR-T cell therapy in hematological malignancies." Current treatment options in oncology. (2023): 184-211.

Key Updates

NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER

NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION

NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY

NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION